Hemispherian
Manufacturing · Norway · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Gaustadalléen 21, Oslo, Oslo, 0349, Norw...Phone Number
+47 40603455Website
www.hemispherian.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Hemispherian
Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company's lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma multiforme, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian is further focused on developing a companion diagnostic tool to support patient selection for optimal therapeutic response to GLIX1. Hemispherian is based in Oslo, Norway.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hemispherian your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Hemispherian recently announced quarterly report
Product Launch: Get notified when Hemispherian launches new products
Website visits: Recent activity has been detected on your website
Check out if Hemispherian is spiking on competitors!
Click to see if Hemispherian had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Hemispherian
Hemispherian, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Hemispherian has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Hemispherian has new funding data
Recommended Actions
Reach out to Masked Content who joined Hemispherian as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Hemispherian is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hemispherian is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hemispherian.
Hemispherian financials insights
Gather financial insights about Hemispherian, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Multiple Rounds
$14.3M
Hemispherian Tech Stack
A closer look at the technologies used by Hemispherian
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
Funding
Funding
Funding
Hemispherian News & Media
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel...BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor ...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology...BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested Results highlight GLIX1's potential to address the high unmet need for patients with GBM TEL AVIV, Israel and OSLO, Norway,...BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center Data from the Phase 1 part of the study anticipated in H1 2027 TEL AVIV, Israel, and OSLO, Norway, April...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hemispherian
Sign Up For FreeTo access detailed company insights
Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company's lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma multiforme,... Read More
